2 results
Approved WMORecruitment stopped
To demonstrate superiority in peak bronchodilator effect of QVM149 at a dose of 150/50/160 *g o.d. and 150/50/80 *g o.d. compared to a FDC ofsalmeterol/fluticasone at a dose of 50/500 *g b.i.d. after 3 weeks of treatment in patients with asthma.
Approved WMOCompleted
Primary objective:- Improvement of walking distance in 6MWT immediately after the first treatment and cumulatively after 3 consecutive treatments with PESFSecundary objectives:- improvement of oxygen saturation - improvement of quality of life-…